Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays

View ORCID ProfileZakarya Abusrewil, View ORCID ProfileInas M Alhudiri, Hamza Hussein Kaal, Salah Edin El Meshri, Fawzi O. Ebrahim, Tarek Dalyoum, Abdussamee A Efrefer, Khaled Ibrahim, Mohammed Ben Elfghi, Suleiman Abusrewil, View ORCID ProfileAdam Elzagheid
doi: https://doi.org/10.1101/2021.05.27.21257868
Zakarya Abusrewil
1Forensic Medicine and toxicology department, University of Tripoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zakarya Abusrewil
Inas M Alhudiri
2Genetic Engineering Department, Biotechnology Research Center, Tripoli, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Inas M Alhudiri
Hamza Hussein Kaal
3Alcala de henares hospitals, Madrid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salah Edin El Meshri
4Microbiology Department, Biotechnology Research Center, Tripoli, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fawzi O. Ebrahim
5Cell Biology Department, Biotechnology Research Center, Tripoli, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tarek Dalyoum
2Genetic Engineering Department, Biotechnology Research Center, Tripoli, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdussamee A Efrefer
2Genetic Engineering Department, Biotechnology Research Center, Tripoli, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khaled Ibrahim
2Genetic Engineering Department, Biotechnology Research Center, Tripoli, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Ben Elfghi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suleiman Abusrewil
6Paediatrics department, University of Tripoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Elzagheid
2Genetic Engineering Department, Biotechnology Research Center, Tripoli, Libya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam Elzagheid
  • For correspondence: elzagheid@yahoo.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background There is a great demand for more rapid tests for SARS-COV-2 detection to reduce waiting time, boost public health strategies for combating disease, decrease costs, and prevent overwhelming laboratory capacities. This study was conducted to assess the performance of 10 antigen-based rapid assays for the detection of SARS-CoV-2 in nasopharyngeal swab specimens.

Methods We analyzed 231 nasopharyngeal samples collected from October 2020-December 2020, from suspected COVID-19 cases and contacts of positive cases at Biotechnology Research Center laboratories, Tripoli, Libya. The performance of 10 COVID-19 Ag rapid test devices (Fluorecare, ESPLINE, RapiGen, Abbott Panbio, Flowflex, Acon, Assut Europe, Orient Gene, CerTest, Bioperfectus, AMP) for the detection of SARS-CoV-2 antigen was compared to RT-qPCR.

Results Among the 108 positive samples detected by RT-qPCR, the COVID-19 antigen (Ag) tests detected 83, giving a sensitivity of 76.85% (95% CI, 67.75-84.43). 161 patients were symptomatic. The median cycle threshold was 25. The mean duration from symptom onset was 6.6 ±4.3 days. Sensitivity and specificity during the first 6 days of symptoms and in samples with high viral loads ct<25, was 96.4%. No false positives were detected by any of the Ag tests utilized in this study. False negative samples had a median Ct of 34 and average duration of onset of symptoms of 11.3 days (range=5-20).

Conclusions Rapid antigen test diagnosis has high sensitivity and specificity in early disease when patients present less than 7 days of symptom onset. Patients are encouraged to test as soon as they get COVID-19 related symptoms within 1 week and to seek medical advice within 24 hrs. if they develop disturbed smell/taste. The use of rapid antigen tests is important for controlling COVID-19 pandemic and reducing burden on molecular diagnostic laboratories.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Bioethics Committee at Biotechnology Research Center

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be available upon request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted May 30, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays
Zakarya Abusrewil, Inas M Alhudiri, Hamza Hussein Kaal, Salah Edin El Meshri, Fawzi O. Ebrahim, Tarek Dalyoum, Abdussamee A Efrefer, Khaled Ibrahim, Mohammed Ben Elfghi, Suleiman Abusrewil, Adam Elzagheid
medRxiv 2021.05.27.21257868; doi: https://doi.org/10.1101/2021.05.27.21257868
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays
Zakarya Abusrewil, Inas M Alhudiri, Hamza Hussein Kaal, Salah Edin El Meshri, Fawzi O. Ebrahim, Tarek Dalyoum, Abdussamee A Efrefer, Khaled Ibrahim, Mohammed Ben Elfghi, Suleiman Abusrewil, Adam Elzagheid
medRxiv 2021.05.27.21257868; doi: https://doi.org/10.1101/2021.05.27.21257868

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (180)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (423)
  • Epidemiology (9004)
  • Forensic Medicine (4)
  • Gastroenterology (421)
  • Genetic and Genomic Medicine (1962)
  • Geriatric Medicine (191)
  • Health Economics (405)
  • Health Informatics (1330)
  • Health Policy (662)
  • Health Systems and Quality Improvement (520)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10826)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1837)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (356)
  • Occupational and Environmental Health (470)
  • Oncology (1003)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (183)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (582)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1910)
  • Public and Global Health (4133)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (370)
  • Respiratory Medicine (551)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (82)